Search company, investor...

Modality Solutions

modality-solutions.com

About Modality Solutions

Modality Solutions is a biopharmaceutical cold chain engineering firm that specializes in designing, qualifying, and validating cold chain packaging, equipment, and processes. It is based in League City, Texas.

Headquarters Location

2600 South Shore Boulevard Suite 364

League City, Texas, 77573,

United States

Missing: Modality Solutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Modality Solutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Modality Solutions Patents

Modality Solutions has filed 1 patent.

The 3 most popular patent topics include:

  • Bayesian statistics
  • Decision theory
  • Food safety
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2020

Bayesian statistics, Pickup trucks, Meteorological data and networks, Food safety, Decision theory

Application

Application Date

2/10/2020

Grant Date

Title

Related Topics

Bayesian statistics, Pickup trucks, Meteorological data and networks, Food safety, Decision theory

Status

Application

Latest Modality Solutions News

FUJIFILM Medical Systems U.S.A. and Helio Health collaborate to advance blood-based screening methods for early-stage liver cancer

May 13, 2021

News FUJIFILM Medical Systems U.S.A. and Helio Health collaborate to advance blood-based screening methods for early-stage liver cancer Collaboration enables acceleration of early cancer detection and surveillance FUJIFILM Medical Systems U.S.A. and Helio Health collaborate to advance blood-based screening methods for early-stage liver cancer. (Credit: Belova59 from Pixabay) FUJIFILM Medical Systems U.S.A., Inc., a leading provider of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC), and Helio Health, an AI-driven healthcare company developing early cancer detection tests, today announced their collaboration to provide a blood-based assay that can help with the earlier detection of liver cancer. Through this relationship, Helio Health’s DNA methylation and biomarker-based blood test technology, recognized as the HelioLiver Test, will leverage Fujifilm’s 510(k)-cleared µTASWako® i30 Immunological test system for liver cancer biomarkers. Liver cancer is the fastest growing and second deadliest cancer worldwide. According to the American Cancer Society, liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. Studies show that early detection of liver cancer is critical to successful outcomes with a survival rate that is 12 times higher if caught in early versus late stages. These statistics underscore the need for more advanced solutions and therapies for early liver cancer detection. “Potential curative treatment options are more readily available when liver cancer is detected at an early stage. We believe that this collaboration will provide expanded monitoring and treatment options for patients at high- risk of developing liver cancer,” said Henry Izawa, Vice President, Modality Solutions and Clinical Affairs, FUJIFILM Medical Systems U.S.A., Inc. “The Fujifilm team is looking forward to leveraging our combined resources to offer market leading technologies that offer clinicians market leading surveillance and diagnostic technologies.” Data presented in November 2020 from the U.S. CLiMB trial, a multi-center, prospective clinical study, suggest that the HelioLiver Test, a multi-analyte HCC-specific blood test, provides greater sensitivity and specificity for the detection of early-stage HCC and disease surveillance in high-risk communities compared to current screening modalities. The positive data from the clinical trial provides further evidence of the HelioLiver Test’s ability to provide earlier detection with greater accuracy for liver cancer and enable groundbreaking advances in the detection and management of this growing disease. The HelioLiver Test is under regulatory review for registration by the China National Medical Products Administration (NMPA). “We are excited to join forces with Fujifilm in our mutual mission to simplify cancer screening with a simple blood draw. Fujifilm has a strong global presence and track record of developing and commercializing diagnostic tests. Fujifilm’s market expertise will also enable us to solidify adoption of the HelioLiver Test in the U.S. market, especially where ultrasound remains the standard of care for early liver cancer detection,” added Kenneth Chahine, Ph.D., J.D., Chief Executive Officer of Helio Health. Source: Company Press Release

Modality Solutions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Modality Solutions Rank

Modality Solutions Frequently Asked Questions (FAQ)

  • Where is Modality Solutions's headquarters?

    Modality Solutions's headquarters is located at 2600 South Shore Boulevard, League City.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.